The investigators will evaluate effects of a novel drug that improves nicotinergic receptor
function vs. placebo on short-term smoking abstinence in smokers with schizophrenia who have
a high interest in quitting. The investigators predict that the novel drug will increase days
of abstinence, compared with placebo, identifying potential evidence of efficacy for smoking
cessation in smokers with schizophrenia.
The investigators will also assess if this new drug decreases nicotine withdrawal, craving,
and cognitive impairment during early abstinence, as well as evaluate adverse effects.
Phase:
Phase 2
Details
Lead Sponsor:
K.N. Roy Chengappa
Collaborators:
National Institutes of Health (NIH) University of Pittsburgh Virginia Commonwealth University